X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs DIVIS LABORATORIES - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES DIVIS LABORATORIES PIRAMAL ENTERPRISES/
DIVIS LABORATORIES
 
P/E (TTM) x 36.6 30.0 121.8% View Chart
P/BV x 3.0 5.2 58.5% View Chart
Dividend Yield % 0.8 1.0 84.1%  

Financials

 PIRAMAL ENTERPRISES   DIVIS LABORATORIES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
DIVIS LABORATORIES
Mar-17
PIRAMAL ENTERPRISES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,0951,222 171.4%   
Low Rs1,025784 130.7%   
Sales per share (Unadj.) Rs492.8153.1 321.9%  
Earnings per share (Unadj.) Rs72.639.9 181.6%  
Cash flow per share (Unadj.) Rs94.744.6 212.3%  
Dividends per share (Unadj.) Rs21.0010.00 210.0%  
Dividend yield (eoy) %1.31.0 135.0%  
Book value per share (Unadj.) Rs862.5201.8 427.4%  
Shares outstanding (eoy) m172.56265.47 65.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.26.6 48.3%   
Avg P/E ratio x21.525.1 85.6%  
P/CF ratio (eoy) x16.522.5 73.3%  
Price / Book Value ratio x1.85.0 36.4%  
Dividend payout %28.925.0 115.6%   
Avg Mkt Cap Rs m269,194266,266 101.1%   
No. of employees `0004.09.7 41.2%   
Total wages/salary Rs m17,9394,687 382.7%   
Avg. sales/employee Rs Th21,190.34,175.0 507.6%   
Avg. wages/employee Rs Th4,470.1481.5 928.4%   
Avg. net profit/employee Rs Th3,120.01,089.3 286.4%   
INCOME DATA
Net Sales Rs m85,03740,643 209.2%  
Other income Rs m2,338749 312.1%   
Total revenues Rs m87,37441,392 211.1%   
Gross profit Rs m34,99114,460 242.0%  
Depreciation Rs m3,8171,233 309.5%   
Interest Rs m20,31023 89,866.4%   
Profit before tax Rs m13,20213,953 94.6%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2813,349 68.1%   
Profit after tax Rs m12,52010,604 118.1%  
Gross profit margin %41.135.6 115.7%  
Effective tax rate %17.324.0 72.0%   
Net profit margin %14.726.1 56.4%  
BALANCE SHEET DATA
Current assets Rs m87,59040,105 218.4%   
Current liabilities Rs m185,5786,595 2,814.1%   
Net working cap to sales %-115.282.5 -139.8%  
Current ratio x0.56.1 7.8%  
Inventory Days Days31119 26.2%  
Debtors Days Days4881 58.9%  
Net fixed assets Rs m108,52319,995 542.8%   
Share capital Rs m345531 65.0%   
"Free" reserves Rs m148,48153,043 279.9%   
Net worth Rs m148,82653,574 277.8%   
Long term debt Rs m144,9570-   
Total assets Rs m482,39461,585 783.3%  
Interest coverage x1.7618.4 0.3%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.7 26.7%   
Return on assets %6.817.3 39.4%  
Return on equity %8.419.8 42.5%  
Return on capital %12.026.1 45.8%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m15,00135,384 42.4%   
Fx outflow Rs m5,15010,399 49.5%   
Net fx Rs m9,85124,985 39.4%   
CASH FLOW
From Operations Rs m-100,39311,493 -873.5%  
From Investments Rs m-24,202-11,372 212.8%  
From Financial Activity Rs m135,705-93 -145,762.2%  
Net Cashflow Rs m11,11028 39,118.7%  

Share Holding

Indian Promoters % 52.9 52.0 101.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 11.8 33.9%  
FIIs % 26.6 19.0 140.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 17.2 95.9%  
Shareholders   93,274 31,796 293.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   IPCA LABS  GSK PHARMA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 23, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS